The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HSCS | +10.23% | N/A | N/A | -98% |
| S&P | +10.51% | +83.8% | +12.94% | +73% |
Heart Test Laboratories, Inc. is a medical technology company focused on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG’s clinical usefulness. Its objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It offers MyoVista, a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. The company was founded in 2008 and is headquartered in Southlake, TX.
No news articles found for HeartSciences.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | 8.4% |
| Gross Margin | -1607.11% | 0.0% |
| Market Cap | $6.04M | 139.1% |
| Market Cap / Employee | $0.40M | 0.0% |
| Employees | 15 | 0.0% |
| Net Income | -$2.05M | -0.2% |
| EBITDA | -$1.84M | 9.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.79M | -35.7% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0.6 | 1.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.28M | -68.9% |
| Short Term Debt | $1.67M | 1465.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -119.88% | 15.3% |
| Return On Invested Capital | -466.82% | -243.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.95M | 3.2% |
| Operating Free Cash Flow | -$1.95M | 3.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.45 | 0.76 | 2.03 | 17.05 | 2799.03% |
| Price to Sales | 160.99 | 183.49 | 897.34 | 650.72 | 93.60% |
| Price to Tangible Book Value | 0.61 | 1.26 | 20.35 | -2.47 | -407.90% |
| Enterprise Value to EBITDA | -0.79 | -1.53 | -3.07 | -1.75 | -1172.95% |
| Return on Equity | -644.2% | -163.5% | -233.0% | -193.2% | -28.24% |
| Total Debt | $2.90M | $2.99M | $2.99M | $1.95M | 92.35% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
